About Wollvac
WOLLVAC
To be a perpetual protector of the animal husbandry industry
Founded in 2005, WollVac is committed to becoming a world-leading enterprise in animal biological products manufacturer. With the mission of "being an eternal umbrella for the aquaculture and livestock industry", we focus on the R&D, production and technical services of animal vaccines and biological products, and safeguard the healthy development of the global animal husbandry industry through technological innovation.
Innovation-Driven · Research-Led
WollVac has established three major scientific research platforms—the Key Enterprise Technology Center, the Animal Pathogenic Microbiology Engineering Laboratory, and the Engineering Technology Research Center for Animal Immunological Adjuvants—forming a complete innovation system that covers the entire process from basic research to achievement transformation. The company has completed the transformation of over 30 scientific and technological achievements, obtained more than 50 national patents, 20 new veterinary drug certificates, and 45 clinical trial approvals.
High-End Team · Professional R&D
We have a high-caliber R&D team consisting of 10 doctors, more than 70 masters, and over 30 research assistants. Focusing on three core fields—poultry diseases, swine diseases, and genetic engineering—the team continuously breaks through key technological bottlenecks.Through the "Hundred-Talent Program for Scientific Research", WollVac continuously recruits top scientific research talents to enhance the company's innovation capability.
Intelligent Manufacturing · Quality Assurance
In 2021, the company invested 100 million yuan in building a high-standard GMP biological products workshop, equipped with advanced systems such as genetic engineering production lines and suspension culture production lines, and passed the certification for the new version of Veterinary Drug GMP in 2022. In 2025, the factory upgraded its production lines again and passed the GMP acceptance inspection conducted by the Ministry of Agriculture.
In 2025, WollVac will invest another 100 million RMB to build a production workshop for highly pathogenic Avian Influenza vaccines. Its products cover the entire poultry vaccine industry chain, providing customers with stable, safe, and high-quality products.
Collaboration for Co-Creation · Future-Oriented
Adhering to the development concept of "integration of industry, academia, and research", WollVac has carried out in-depth cooperation with top scientific research institutions such as China Agricultural University and the Chinese Academy of Agricultural Sciences (CAAS), continuously promoting the innovative application of new technologies and new products.
In the future, WollVac will continue to take technological innovation as its core driving force and provide safer, more efficient, and more reliable biological product solutions for the global aquaculture and livestock industry.
Research & Development Team
We have a high-level R&D team consisting of 10 PhDs, over 70 Masters, and over 30 research assistants, focusing on three major areas: poultry diseases, swine diseases, and genetic engineering, and continuously breaking through core technological bottlenecks.
Dr. Niu
Doctor of Engineering, Postdoctoral Fellow in Veterinary Medicine.
Dr. Lee
Postdoctoral fellow, licensed veterinarian in China, visiting scholar at Pennsylvania State University, USA.
Dr. Zhang
Working on diagnosis and treatment, defense and control of livestock and poultry diseases.
Dr. Zhu
Researcher, University of Saskatchewan, Canada, Visiting Scholar, Agency for AIVM.
Dr. Quan
Doctor, researcher, mainly engaged in preventive veterinary research.
Dr. Geng
Ph.D. in Zoology, Visiting Scholar at the University of Arkansas, U.S.A.
Dr. Xu
Researcher, Doctor of Veterinary Medicine, National Professional Veterinarian.
Dr. Jiao
Professor, Executive Director of China Veterinary Medical Association.
Production bases & global layout
- Domestic production base: XX0,000 square meters of modern factory buildings, compliant with GMP/WHO standards, with an annual production capacity of X billion doses.
- Cold chain logistics center: Temperature monitoring throughout the process, in compliance with IATA standards, to ensure the quality of vaccine transportation.
- Covering over 50 countries in Southeast Asia, the Middle East, Central Asia, and Africa, we have established localized service centers. We partner with local wholesalers to provide customized vaccine solutions.
Need help?
Contact us for the latest vaccine information and technical support!